Zhe Bao Wu

ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 18

Top Venues

Acta neuropathologica communications

Nature reviews. Endocrinology

Neuro-oncology

Cancers

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital Mar 14 2014

China

Professor :: Neurosurgery

Publications

Yijun Cheng, Dapeng Wang, Hao Tang, Debing Tong, Weiguo Zhao, Shaojian Lin, Hong Yao, Wenwen Lv, Xun Zhang, Li Xue, Hanbing Shang, Zhe Bao Wu
Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas. Cancers 16 (4) (2024)
Yijun Cheng, Yuting Dai, Hao Tang, Xingyu Lu, Jing Xie, Wanqun Xie, Qianqian Zhang, Yanting Liu, Shaojian Lin, Hong Yao, Hanbing Shang, Kun Yang, Hongyi Liu, Xuefeng Wu, Jianming Zhang, Xun Zhang, Li Xue, Zhe Bao Wu
Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors. Acta neuropathologica communications 12 (1) (2024)
Zhe Bao Wu
The shift of therapeutic strategy for prolactinomas: surgery as the first-line option. Nature reviews. Endocrinology (2024)
Zhe Bao Wu
The shift of therapeutic strategy for prolactinomas: surgery as the first-line option. Nature reviews. Endocrinology (2024)
Yijun Cheng, Yuting Dai, Hao Tang, Xingyu Lu, Jing Xie, Wanqun Xie, Qianqian Zhang, Yanting Liu, Shaojian Lin, Hong Yao, Hanbing Shang, Kun Yang, Hongyi Liu, Xuefeng Wu, Jianming Zhang, Xun Zhang, Li Xue, Zhe Bao Wu
Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors. Acta neuropathologica communications 12 (1) (2024)
Bo Zhang, Li Xue, Zhe Bao Wu
Structure and Function of Somatostatin and its Receptors in Endocrinology. Endocrine reviews (2024)
Shaojian Lin, Liangbo Wang, Changxi Han, Yuting Dai, Changsheng Li, Yanting Liu, Bo Zhang, Ning Huang, Anke Zhang, Tao Zhang, Yu Wang, Jing Xie, Hao Tang, Yijun Cheng, Hong Yao, Meiqing Lou, Li Xue, Zhe Bao Wu
Targeting HTR2B suppresses non-functioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis. Neuro-oncology (2024)
Yijun Cheng, Yuting Dai, Hao Tang, Xingyu Lu, Jing Xie, Wanqun Xie, Qianqian Zhang, Yanting Liu, Shaojian Lin, Hong Yao, Hanbing Shang, Kun Yang, Hongyi Liu, Xuefeng Wu, Jianming Zhang, Xun Zhang, Li Xue, Zhe Bao Wu
Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors. Acta neuropathologica communications 12 (1) (2024)
Yijun Cheng, Dapeng Wang, Hao Tang, Debing Tong, Weiguo Zhao, Shaojian Lin, Hong Yao, Wenwen Lv, Xun Zhang, Li Xue, Hanbing Shang, Zhe Bao Wu
Alternations of Blood Pressure Following Surgical or Drug Therapy for Prolactinomas. Cancers 16 (4) (2024)
Yijun Cheng, Yuting Dai, Hao Tang, Xingyu Lu, Jing Xie, Wanqun Xie, Qianqian Zhang, Yanting Liu, Shaojian Lin, Hong Yao, Hanbing Shang, Kun Yang, Hongyi Liu, Xuefeng Wu, Jianming Zhang, Xun Zhang, Li Xue, Zhe Bao Wu
Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors. Acta neuropathologica communications 12 (1) (2024)
Zhe Bao Wu
The shift of therapeutic strategy for prolactinomas: surgery as the first-line option. Nature reviews. Endocrinology 20 (5) (2024)
Hao Tang, Yijun Cheng, Xiaohui Lou, Hong Yao, Jing Xie, Weiting Gu, Xinyun Huang, Yanting Liu, Shaojian Lin, Yuting Dai, Li Xue, Xiaozhu Lin, Zhe Bao Wu
DRD2 expression based on 18 F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study. Endocrine (2023)
Hong Yao, Wanqun Xie, Yuting Dai, Yanting Liu, Weiting Gu, Jian-Feng Li, Liang Wu, Jing Xie, Weiwei Rui, Bohan Ren, Li Xue, Yijun Cheng, Shaojian Lin, Changsheng Li, Hao Tang, Yu Wang, Meiqing Lou, Xiaobiao Zhang, Ronggui Hu, Hanbing Shang, Jinyan Huang, Zhe Bao Wu
TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT. Neuro-oncology 24 (8) (2022)
Wei Ting Gu, Fen Zhou, Wan Qun Xie, Shuo Wang, Hong Yao, Yan Ting Liu, Ling Gao, Zhe Bao Wu
A potential impact of SARS-CoV-2 on pituitary glands and pituitary neuroendocrine tumors. Endocrine 72 (2) (2021)
Yan Ting Liu, Fang Liu, Lei Cao, Li Xue, Wei Ting Gu, Yong Zhi Zheng, Hao Tang, Yu Wang, Hong Yao, Yong Zhang, Wan Qun Xie, Bo Han Ren, Zhuo Hui Xiao, Ying Jie Nie, Ronggui Hu, Zhe Bao Wu
The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment. Acta neuropathologica 140 (3) (2020)
Hai Yan Huang, Shao Jian Lin, Wei Guo Zhao, Zhe Bao Wu
Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review. Metabolic brain disease 33 (3) (2018)
Ze Rui Wu, Lichong Yan, Yan Ting Liu, Lei Cao, Yu Hang Guo, Yong Zhang, Hong Yao, Lin Cai, Han Bing Shang, Wei Wei Rui, Gang Yang, Xiao Biao Zhang, Hao Tang, Yu Wang, Jin Yan Huang, Yong Xu Wei, Wei Guo Zhao, Bing Su, Zhe Bao Wu
Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours. Nature communications 9 (1) (2018)
Ze Rui Wu, Yong Zhang, Lin Cai, Shao Jian Lin, Zhi Peng Su, Yong Xu Wei, Han Bing Shang, Wen Lei Yang, Wei Guo Zhao, Zhe Bao Wu
Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup. International journal of endocrinology 2016 (2016)

Zhe Bao Wu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Zhe Bao Wu